Stemline Therapeutics, Inc. (STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, announced that ELZONRIS™ (tagraxofusp) is the subject of three clinical presentations at the Congress of the European Hematology Association (EHA). Data from the ongoing Phase 1/2 trials in chronic myelomonocytic leukemia (CMML) and myelofibrosis (MF), as well as the results from the pivotal trial in blastic plasmacytoid dendritic cell neoplasm (BPDCN) will be delivered via poster presentation at the 24th Congress of the European Hematology Association (EHA) in Amsterdam, Netherlands.
ELZONRIS (tagraxofusp) is FDA-approved for the treatment of patients, adults and pediatric 2 years and older, with blastic plasmacytoid dendritic cell neoplasm (BPDCN), and is commercially available in the U.S.
Presentations will be available on the Stemline website (www.stemline.com) Scientific Presentations tab, after their delivery.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.